Researchers have found why PSA (prostate-specific antigen) levels reflect cancer progression.
"This is the first demonstration of a mechanism that explains why PSA is a bad thing for a tumour to produce," said senior author Sal Pizzo, chair of the Duke Department of Pathology.
"I am willing to bet there is also a connection in cancerous cell growth with this particular biological signalling mechanism happening in other types of cells," he added.
The PSA forms a complex with the antibody that also binds to the GRP78 receptor, and that activates several key pathways, which stimulate cancer cell growth and cell movement and block cell death.
The study bolsters the case for measuring PSA as a marker of tumour progression, as well as for monitoring for a2M antibody levels.
"I personally believe PSA is more useful as a progression marker, particularly with a baseline value on record at the time of the original therapy. A rapidly rising value and/or a very high value is reason for concern. I also believe that monitoring the serum for the appearance of antibodies directed against GRP78 is also a good marker of progression," said Pizzo.
He said that the findings could yield cancer therapies that block the a2M-PSA complex from stimulating the cell receptor signalling cascade, and that his laboratory is investigating possibilities.
The findings might also yield new kinds of early-detection tests for prostate cancer.
Pizzo credits lead author Uma Misra with deducing that PSA may be involved in a signalling feedback loop that promotes more aggressive behaviour in the human prostate cancer cells.
Years ago, Misra discovered the GRP78 receptor on the prostate tumor cell surface, the receptor that binds the a2M antibody and the a2M-PSA complex.
"We were surprised to find that this complex binds with the protein GRP78, because we thought the GRP78 molecule only lived deep inside the cell, where it was busy taking improperly folded proteins and helping them to fold properly," said Pizzo.
The study is published in the current edition of the Journal of Biological Chemistry.